Adiponectinemia Is Associated with Uricemia but Not with Proinflammatory Status in Women with Metabolic Syndrome

Table 1

Clinical and laboratory characteristics of patients with metabolic syndrome and controls.

	Metabolic Syndrome (𝑛=60)	Controls (𝑛=31)	𝑃
Age (years)	45.0 (25.0–60.0)	41.5 (25.0–54.0)	0.1257
Smoking/no smoking	2/58	1/30	0.6379
BMI (m/kg^2)	37.2 (27.1–53.9)	22.9 (20.1–24,5)	<0.0001
WC (cm)	110.0 (88.0–157.0)	79.0 (61.0–86.0)	<0.0001
SBP (mmHg)	134.5 (99.0–203.0)	101.0 (81.0–130.0)	<0.0001
DBP (mmHg)	83.0 (62.0–124.0)	65.0 (47.0–80.0)	<0.0001
Triacylg (mg/dL)	202.0 (40.0–401.0)	70.0 (32.0–135.0)	<0.0001
HDL (mg/dL)	39.0 (19.0–81.0)	58.5 (51.0–77.0)	<0.0001
Fasting glucose (mg/dL)	100.5 (74.0–195.0)	80.0 (71.0–93.0)	<0.0001
Fasting insulin (μU/mL)	18.50 (4.10–75.40)	4.40 (2.90–9.80)	<0.0001
HOMA	4.47 (0.83–36.24)	0.84 (0.57–1.79)	<0.0001
Uric acid (mg/dL)	5.51 (3.15–9.65)	3.38 (2.07–4.73)	<0.0001

Data are median (minimum–maximum).
BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; Triacylg: triacylglycerol; HDL: High-density lipoprotein; HOMA: Homeostasis model of assessment.